Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-003008.pdf
0001179110-21-003008.rtf
0001179110-21-003008.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-003010.pdf
0001179110-21-003010.rtf
0001179110-21-003010.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-003011.pdf
0001179110-21-003011.rtf
0001179110-21-003011.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-003012.pdf
0001179110-21-003012.rtf
0001179110-21-003012.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-003013.pdf
0001179110-21-003013.rtf
0001179110-21-003013.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002645.pdf
0001179110-21-002645.rtf
0001179110-21-002645.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002648.pdf
0001179110-21-002648.rtf
0001179110-21-002648.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002646.pdf
0001179110-21-002646.rtf
0001179110-21-002646.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002654.pdf
0001179110-21-002654.rtf
0001179110-21-002654.xls
4

Statement of changes in beneficial ownership of securities

 View HTML
0001179110-21-002651.pdf
0001179110-21-002651.rtf
0001179110-21-002651.xls